tbuckley/cabot-search huggingface dataset:
School-based depression and anxiety prevention programs for young people: A systematic review and meta-analysis
Authors: Aliza Werner-Seidler, Yael Perry, Alison L. Calear, Jill M. Newby, Helen Christensen
Journal: Clinical Psychology Review (2016)

Depression and anxiety often emerge for the first time during youth. The school environment provides an ideal context to deliver prevention programs, with potential to offset the trajectory towards disorder. The aim of this review was to provide a comprehensive evaluation of randomised-controlled trials of psychological programs, designed to prevent depression and/or anxiety in children and adolescents delivered in school settings. Medline, PsycINFO and the Cochrane Library were systematically searched for articles published until February 2015. Eighty-one unique studies comprising 31,794 school students met inclusion criteria. Small effect sizes for both depression (g = 0.23) and anxiety (g = 0.20) prevention programs immediately post-intervention were detected. Small effects were evident after 12-month follow-up for both depression (g = 0.11) and anxiety (g = 0.13). Overall, the quality of the included studies was poor, and heterogeneity was moderate. Subgroup analyses suggested that universal depression prevention programs had smaller effect sizes at post-test relative to targeted programs. For anxiety, effect sizes were comparable for universal and targeted programs. There was some evidence that externally-delivered interventions were superior to those delivered by school staff for depression, but not anxiety. Meta-regression confirmed that targeted programs predicted larger effect sizes for the prevention of depression. These results suggest that the refinement of school-based prevention programs have the potential to reduce mental health burden and advance public health outcomes.
Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.
Authors: Jessica Pollard, Todd Alonzo, Robert Gerbing, Rong Zeng, Betsy Hirsch, Susana Raimondi, Nyla Heerema, William Woods, Beverly Lange, Craig Hurwitz, Robert Arceci, Jerald Radich, Irwin Bernstein, Michael Heinrich, Soheil Meshinchi
Journal: Blood (2007)
GW26-e4703 Efficacy and safety of eplerenone compared to amlodipine in Chinese adults with hypertension: an 8-week, multicenter, randomized, double-blind, parallel-group study
Authors: Zhijun Huang, Zhihao Shu, Yin Li, Deming Chen, Ying Guan, Xiuli Zhao, Shuiping Zhao, Hong Yuan
Journal: Journal of the American College of Cardiology (2015)
A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease.
Authors: Jorge Cortes, James M. Reuben, David Scheinberg, Bang-Ning Lee, Hui Gao, Changping Li, Rosemary Mazanet, Dan Jones, Hagop Kantarjian
Journal: Blood (2006)
Evaluation of clinicopathological features from core needle biopsy and CT imaging as predictors of response to primary systemic therapy for operable breast cancer
Authors: T. Shien, S. Akashi-Tanaka, C. Shimizu, T. Hojo, K. Seki, T. Kohno, M. Ando, N. Katsumata, Y. Fujiwara, T. Kinoshita
Journal: Journal of Clinical Oncology (2007)

11086 Background: Primary systemic therapy (PST) is standard therapy for patients with locally advanced breast cancer and increasingly used for early-stage operable disease. Clinical and pathologic responses are important prognostic parameters and clinicopathological markers to predict response to PST are needed to individualize treatment. Methods: From 1998 to 2005, 403 primary breast cancer patients were underwent curative surgical treatment after PST (Anthlacycline and/or Taxane) at NCCH. We retrospectively evaluated the clinicopathological features (age, histological type, histological grade, ER, PgR and HER-2) and classification of tumors using CT (localized tumor type and diffused tumor type) at before PST and analyzed the correlation with clinical response and pathological complete response (pCR). The log-rank statistic was used for univariate comparisons and multivariate analysis performed using Cox hazard model. Results: Overall response and pCR rate were 87% and 18%. Breast conserving surgery was performed 37% patients. Histological grade 3 (p&lt;0.0001), ER negative (p&lt;0.0001), PgR negative (p&lt;0.0001), solid-tubular type (p=0.0006), age (&gt;50) (p=0.008) and localized tumor type (p=0.02) correlated with pCR. In multivariate analysis, Histological grade 3 (p=0.01) and localized tumor type (p=0.036) were independent predictors for pCR. ER positive, histological grade 2 or 1, invasive lobular carcinoma and diffuse tumor type associated with low chemosensitivity and low breast conserving surgery rate. Conclusions: Clinical and pathological response significantly associated with ER status and histological grade. Furthermore the classification of tumor type using CT was effective to predict of response to PST. No significant financial relationships to disclose.
Advances in Sequencing Technologies for Understanding Hereditary Ataxias
Authors: Alessandro Didonna, Puneet Opal
Journal: JAMA Neurology (2016)

The hereditary progressive ataxias comprise genetic disorders that affect the cerebellum and its connections. Even though these diseases historically have been among the first familial disorders of the nervous system to have been recognized, progress in the field has been challenging because of the large number of ataxic genetic syndromes, many of which overlap in their clinical features.We have taken a historical approach to demonstrate how our knowledge of the genetic basis of ataxic disorders has come about by novel techniques in gene sequencing and bioinformatics. Furthermore, we show that the genes implicated in ataxia, although seemingly unrelated, appear to encode for proteins that interact with each other in connected functional modules.It has taken approximately 150 years for neurologists to comprehensively unravel the genetic diversity of ataxias. There has been an explosion in our understanding of their molecular basis with the arrival of next-generation sequencing and computer-driven bioinformatics; this in turn has made hereditary ataxias an especially well-developed model group of diseases for gaining insights at a systems level into genes and cellular pathways that result in neurodegeneration.
Elevated Procoagulant Microparticles Expressing Endothelial and Platelet Markers in Essential Thrombocythemia
Authors: Marijke Trappenburg, Muriel van Schilfgaarde, Marina Marchetti, Henri Spronk, Hugo ten Cate, Anja Leyte, Wim Terpstra, Anna Falanga
Journal: Blood (2008)
Parent-mediated social communication therapy for young children with autism (PACT): long-term follow-up of a randomised controlled trial
Authors: Andrew Pickles, Ann Le Couteur, Kathy Leadbitter, Erica Salomone, Rachel Cole-Fletcher, Hannah Tobin, Isobel Gammer, Jessica Lowry, George Vamvakas, Sarah Byford, Catherine Aldred, Vicky Slonims, Helen McConachie, Patricia Howlin, Jeremy R Parr, Tony Charman, Jonathan Green
Journal: The Lancet (2016)

<h2>Summary</h2><h3>Background</h3> It is not known whether early intervention can improve long-term autism symptom outcomes. We aimed to follow-up the Preschool Autism Communication Trial (PACT), to investigate whether the PACT intervention had a long-term effect on autism symptoms and continued effects on parent and child social interaction. <h3>Methods</h3> PACT was a randomised controlled trial of a parent-mediated social communication intervention for children aged 2–4 years with core autism. Follow-up ascertainment was done at three specialised clinical services centres in the UK (London, Manchester, and Newcastle) at a median of 5·75 years (IQR 5·42–5·92) from the original trial endpoint. The main blinded outcomes were the comparative severity score (CSS) from the Autism Diagnostic Observation Schedule (ADOS), the Dyadic Communication Assessment Measure (DCMA) of the proportion of child initiatiations when interacting with the parent, and an expressive-receptive language composite. All analyses followed the intention-to-treat principle. PACT is registered with the ISRCTN registry, number ISRCTN58133827. <h3>Findings</h3> 121 (80%) of the 152 trial participants (59 [77%] of 77 assigned to PACT intervention <i>vs</i> 62 [83%] of 75 assigned to treatment as usual) were traced and consented to be assessed between July, 2013, and September, 2014. Mean age at follow-up was 10·5 years (SD 0·8). Group difference in favour of the PACT intervention based on ADOS CSS of log-odds effect size (ES) was 0·64 (95% CI 0·07 to 1·20) at treatment endpoint and ES 0·70 (95% CI −0·05 to 1·47) at follow-up, giving an overall reduction in symptom severity over the course of the whole trial and follow-up period (ES 0·55, 95% CI 0·14 to 0·91, p=0·004). Group difference in DCMA child initiations at follow-up showed a Cohen's <i>d</i> ES of 0·29 (95% CI −0.02 to 0.57) and was significant over the course of the study (ES 0·33, 95% CI 0·11 to 0·57, p=0·004). There were no group differences in the language composite at follow-up (ES 0·15, 95% CI −0·23 to 0·53). <h3>Interpretation</h3> The results are the first to show long-term symptom reduction after a randomised controlled trial of early intervention in autism spectrum disorder. They support the clinical value of the PACT intervention and have implications for developmental theory. <h3>Funding</h3> Medical Research Council.
Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.
Authors: Barbara A. Konkle, Liselotte S. Ebbesen, Ute Friedrich, Raul P. Bianco, Toshko Lissitchkov, Luminita Rusen, Margit A. Serban
Journal: Blood (2006)
CpG-b oligodeoxynucleotides potently activate human NK cells and sensitize chronic lymphocytic leukemia cells to NK cell-mediated killing.
Authors: V. Bachanova, X. Liang, A. S. Chan, A. J. Peterson, L. Y. Chen, P. T. Robertson, A. Panoskaltsis-Mortari, B. R. Blazar, J. S. Miller, W. Chen
Journal: Journal of Clinical Oncology (2010)

10553 Background: CpG-B ODNs offer therapeutic applications in cellular immunotherapy. Targeting toll-like receptor 9 (TLR9) expressed on human CLL cells with CpG-B ODN induces activation and immunogenicity of CLL cells. CpG-B ODNs are also known to indirectly activate NK cells. Here, we investigated the mechanism and effect of CpG ODN on NK cell mediated CLL tumor killing. Methods: Primary CLL cells were isolated from peripheral blood of CLL patients and cultured for 72 hours with/without CpG-B ODNs (CpG 2006, CpG 685), analyzed for NK ligand expression by flow cytometry, and used as targets in NK cytotoxicity assays. Peripheral blood mononuclear cells (PBMC) from healthy donors, CLL patients, and CLL patients post-allogeneic hematopoietic cell transplantation (HCT) were treated with/without CpG-B ODNs for 48 hours, analyzed for NK cell activation receptor expression by flow cytometry and cytokine production by ELISA, and used as effectors in NK cytotoxicity assays. Results: NK cells in CpG-treated PBMCs significantly increased their surface expression of CD69, CD154, and NKp30. CpG-treated NK cells showed 4.7-fold (median, n = 10) higher IFN-γ production and a 4.2-fold (median, n = 10) increase in cytolytic activity compared to untreated NK cells. We confirmed that the mechanism of CpG-induced NK cell activation is dependent on type-I IFNs produced by CpG-activated plasmacytoid dendritic cells present in PBMC. Using CpG-treated PBMC from CLL patients against allogeneic CLL tumors, we demonstrated a median 2.5-fold increase (n = 5) in NK cell-mediated killing compared to untreated NK cells. To further analyze donor-derived NK cells in CLL patients post-allogeneic HCT, we demonstrated a 3.0-fold (median; range 1.9-4.5 fold; n = 5) increase in NK cell cytolytic activity by comparing CpG and non-CpG cultures. Additionally, CLL cells exposed to CpG-B ODN for 72 hours acquired ligands for NKG2D, NKp30, NKp44, NKp46, suggesting the potential role of these NK ligand interactions in NK cell-mediated killing. Conclusions: CpG ODNs may provide a novel strategy to manipulate antitumor immunity in CLL patients. No significant financial relationships to disclose.
P0676 : Clearance of persistent hepatitis c virus infection using a monoclonal antibody specific for tight junction protein claudin-1
Authors: L. Mailly, F. Xiao, J. Lupberger, G.K. Wilson, P. Aubert, F.H. Duong, D. Calabrese, C. Leboeuf, I. Fofana, C. Thumann, S. Bandiera, M. Lütgehetmann, T. Volz, C. Davis, H.J. Harris, C. Mee, E. Girardi, B. Chane-Woon-Ming, M. Ericsson, N. Fletcher, R. Bartenschlager, P. Pessaux, K. Vercauteren, P. Meuleman, P. Villa, L. Kaderali, S. Pfeffer, M.H. Heim, M. Neunlist, M.B. Zeisel, M. Dandri, J.A. McKeating, E. Robinet, T.F. Baumert
Journal: Journal of Hepatology (2015)
陳旧性心筋梗塞(OMI)患者の心臓トロポニンT値の上昇は臨床的予後悪化の指標となる
Authors: Shimizu Masahiko, Sato Hiroshi, Sakata Yasuhiko, Nakatani Daisaku, Nizuno Hiroya, Suna Shinichiro, Hori Masatsugu
Journal: Circulation (2007)
Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)
Authors: Stefani Parmentier, Michael Kramer, Katharina Koch, Brigitte Mohr, Christian Klesse, Christian Thiede, Christoph Röllig, Mathias Hänel, Norbert Schmitz, Kerstin Schäfer-Eckart, Walter E. Aulitzky, Wolfgang E. Berdel, Hubert Serve, Stefan W. Krause, Jiri Mayer, Martin Bornhäuser, Gerhard Ehninger, Markus Schaich
Journal: Blood (2012)
Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST
Authors: W. H. Zhan
Journal: Journal of Clinical Oncology (2007)

10045 Background: GIST has a high recurrenc e rate and disease-related mortality even after completed resection of primary tumor. Imatinib(IM) has shown tremendous efficacy in treating patients with metastatic and unresectable GISTs. The primary objective of the study was to evaluate the efficacy and safety of adjuvant post-surgical therapy with IM in GIST patients who had high risk to relapse. Methods: This prospective, open-label, multi-center trial was conducted in 16 hospitals in China. Patient eligibility criteria included patients &gt;18 years old, diagnosed with CD117+ GIST of either =5cm macroscopic tumor size or = 5/50 HPF in mitosis count pathologically. Patients were started on IM 400mg/d for at least 12 months within 4 weeks after completed resection. Primary endpoint was relapse or metastasis rates. Secondary endpoints were disease free survival (DFS), overall survival rate (OSR) and quality of life. From Aug 16 2004 to Sep 13 2005, 57 patients (34 men) enrolled in the trial and average age of patients was 50.6. The primary tumor location was stomach in 50.9%, small intestine in 38.6%. Tumors size was &gt;5cm in 92.9% of patients, and 73.7% of patients had a mitosis count over 5/50 HPF. The majority of patients tested positive for CD34 (82.5%) and negative SMA, S-100 and Desmin results. Results: Of 57 patients, as of date of data cut-off (Dec 31, 2006) 51 patients were included in the ITT analysis and 43 patients (75.4%) finished at least 12 months of IM treatment, and Tumor relapses or metastasis were identified in 2 patients (3.92%) 350 and 680 days post-operation. No death was reported. Median DFS was 385 days. 57.89% of the safety population had adverse events. No serious adverse event reported. 50.88% of the safety population had adverse events related to the treatment of IM based on the determination of investigators. The score in quality of life showed no statistically significant difference between the baseline and the follow-up visits. Conclusions: IM is a promising adjuvant post-surgical therapy in patients with high risk of relapsing GIST. But the optimal doses and duration of adjuvant treatment are still unknown. On the basis of this study, a multi-institutional randomized controlled trial will be necessary. No significant financial relationships to disclose.
The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.
Authors: Richard W.J. Groen, Frans M. Hofhuis, Henk-Jan Prins, Henk Rozemuller, Berris van Kessel, Michel de Weers, Henk Lokhorst, Anton C.M. Martens
Journal: Blood (2009)
Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor draining lymph nodes in primary lung cancer patients
Authors: H. Kimura, T. Iizasa, A. Ishikawa
Journal: Journal of Clinical Oncology (2007)

3048 Background: We conducted a phase II study to evaluate the efficacy and toxicity of adjuvant chemo-immunotherapy using dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes (TDLN) in primary lung cancer patients. Methods: Pathological N2 lung cancer patients were selected for the post-surgical adjuvant chemo-immunotherapy. Activated killer cells and dendritic cells obtained from tissue cultures of TDLN or TDLN co-cultured with peripheral blood lymphocytes (TDLN-Pb) were used for the adoptive transfer of immunotherapy. Patients received 4 courses of post-surgical chemotherapy or chemotherapy along with immunotherapy (immunotherapy group) every 2 months for 2 years. Results: There were 57 N2 patients eligible for the study, 28 for immunotherapy and 29 for chemotherapy. For the 28 immunotherapy cases, a total of 313 courses of immunotherapy were administered. The main toxicities were fever (78.0%), chill (83.4%). The 5-year survival rates in the immunotherapy and chemotherapy groups were 56.5% and 12.5% respectively. Among the variables analyzed, immunotherapy was the most significant independent prognostic factor (p=0.0042.) Conclusions: Adoptive transfer of activated killer cells and dendritic cells from the tumor draining lymph nodes of primary lung cancer patients is safe and feasible, and a large-scale multi-institutional study is necessary for the evaluation of the efficacy of this treatment. No significant financial relationships to disclose.
Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,
Authors: Christopher E. Mason, Maurizio Di Liberto, Xiangao Huang, David Chiron, Jamieson Bretz, Ramsey Abdallah, Scott A Ely, Daniel M Knowles, Peter Martin, John P. Leonard, Selina Chen-Kiang
Journal: Blood (2011)
Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery
Authors: Xin Zhao, Xingmin Feng, Danielle M. Townsley, Thomas Winkler, Ronan Desmond, Matthew J. Olnes, Harshraj Leuva, Bogdan Dumitriu, Cynthia E. Dunbar, Neal S. Young
Journal: Blood (2015)
GW26-e1037 Tanshinones IIA Attenuated Oxidative Stress and Restored Balance between Pro- and Anti-inflammatory Cytokines in Hypothalamic Paraventricular Nucleus Contribute to Sympathoexcitation in Chronic High-Salt Intake Induced Hypertension
Authors: Zhiming Yang, HuiYu Yang, ShiGuo juan, YunFei Bian, Bin Liang, Rui Bai
Journal: Journal of the American College of Cardiology (2015)
Activation of mismatch repair protects cells against ganciclovir cytotoxicity through decreasing errors in DNA replication
Authors: Jessica O'Konek, Paul Boucher, Donna Shewach
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

4038 

Suicide gene therapy with herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) is notable for producing multi-log cytotoxicity in a unique pattern of delayed cell death. This cytotoxicity can be enhanced by the addition of hydroxyurea (HU), a ribonucleotide reductase inhibitor that decreases dNTP pools, which combined with GCV produces additive or synergistic cytotoxicity in many tumor cell types. Because the HU-mediated imbalance in dNTP pools activates mismatch repair (MMR), we evaluated the role of MMR in GCV + HU cytotoxicity. Using isogenic HCT116TK (HSV-TK-expressing) colon carcinoma cells that are deficient or proficient in MMR, cell survival studies demonstrated greater GCV sensitivity in the MMR- compared to the MMR+ cells, primarily at high concentrations. The combination of GCV and HU exhibited additive cytotoxicity in MMR- cells but resulted in antagonism in the MMR+ cells.

To understand the molecular basis for the sparing of GCV cytotoxicity in MMR+ cells, we measured the nature and frequency of mutations following exposure to GCV and/or HU using a shuttle vector mutation assay. There was no significant difference in the basal mutation frequency of untreated cells between the HCT116TK MMR+ and MMR- cell lines (0.062 ± 0.032% and 0.116 ± 0.0049%, respectively; p=0.116). A 24 hr incubation with GCV resulted in similar mutation frequencies in both the MMR+ and MMR- cell lines (0.16 ± 0.018% and 0.16 ± 0.014, respectively) that were not different from controls. Treatment with HU resulted in a significant increase in mutation frequency in the MMR- cells (0.307 ± 0.016%; p=0.0004), but not in the MMR+ cells (0.0320 ± 0.017%; p=0.495) compared to untreated controls. Interestingly, the predominance of a unique transversion mutation (C->A) was observed following incubation with GCV alone in both cell lines, whereas HU induced single base substitutions in which no single mutation predominated. The combined treatment with GCV and HU produced a further increase in mutation frequency in the MMR- cell line (0.379 ± 0.030%) and an increase in HU-associated mutations. However, in the MMR+ cell line, the GCV + HU resulted in a decrease in the mutation frequency (0.0784 ± 0.042 %), although the unique C->A mutation still predominated. These data demonstrated that the unique GCV-associated mutation was neither detected nor repaired by MMR. In addition, the data suggest that the additive cytotoxicity with GCV and HU in the MMR- cells may be due to an increase in errors in DNA replication. However, in the MMR+ cell line, the addition of HU activates MMR which decreases replication errors, resulting in antagonistic cytotoxicity. Taken together, these results demonstrate that activation of MMR protects cells against GCV cytotoxicity.
Preferential expression of domain cassettes 4, 8 and 13 of Plasmodium falciparum erythrocyte membrane protein 1 in severe malaria imported in France
Authors: N. Argy, G.I. Bertin, J. Milet, V. Hubert, J. Clain, S. Cojean, P. Houzé, N. Tuikue-Ndam, E. Kendjo, P. Deloron, S. Houzé, S. Matheron, E. Casalino, M. Wolff, A. Delaval, P. Agnamey, R. Durand, J.E. Pilo, C. Rapp, J.F. Faucher, B. Cuisenier, I. Poilane, D. Bemba, A. Roide, A. Debourgogne, M. Thibault, D. Toubas, P. Patoz, L. De Gentile, D. Pons, J.P. Hurst, C. Lohmann, M.L. Bigel, N. Godineau, M. Thouvenin, J. Dunand, N. Ait-Ammar, A. Angoulvant, N. Dahane, M. Lefevre, J.B. Murat, C. Garnaud, E. Dannaoui, F. Botterel, E. Dutoit, M.L. Dardé, H. Ichou, C. Branger, P. Penn, C. Angebault, F. Morio, L. Bret, M. Thellier, O. Mouri, E. Cateau, J.Y. Siriez, O. Fenneteau, M. Revest, S. Belaz, G. Belkadi, S. Hamane, S. Bretagne, A. Aboubacar, G. Leloup, M. Develoux, H. Lapillonne, O. Eloy, G. Nevez, D. Raffenot, B. Buret, G. Desoubeaux, A. Goepp
Journal: Clinical Microbiology and Infection (2016)
GW26-e1243 Inhibitory Effects of Hirudin on the Growth and Proliferation of Human Coronary Artery Smooth Muscle Cells and Endothelial Cells in Vitro
Authors: Hongmei Li, Mengqiong Sun, Ang Gao, Zhen Wang, Xueqing Yang, Tian Sun, Changbo Xuan, Xian Wang
Journal: Journal of the American College of Cardiology (2015)